Novo Nordisk to launch new diabetes therapy in Japan
Tresiba is the new once-daily basal insulin with an ultra-long duration of action for the treatment of type 1 and type 2 diabetes. Tresiba successfully achieved equivalent reductions
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.